Adagrasib Improves PFS, ORR in Previously Treated KRAS G12C–Mutant NSCLC
Adagrasib improved progression-free survival and objective response rates vs docetaxel in pretreated KRAS G12C–mutant non–small cell lung cancer.
Adagrasib improved progression-free survival and objective response rates vs docetaxel in pretreated KRAS G12C–mutant non–small cell lung cancer.
The FDA granted accelerated approval to tovorafenib for pediatric patients relapsed/refractory low-grade glioma with a BRAF fusion/rearrangement or a BRAF V600 mutation.
The FDA has approved lutetium Lu 177 dotatate for pediatric patients 12 years of age and older with SSTR)–positive GEP-NETs.
An abstract is unavailable.
After noticing a lump on the right side of his neck, Chu Nguyen, Ph.D., came to MD Anderson for a second opinion. Further testing revealed…
The field of central nervous system (CNS) oncology is rapidly changing with advances in molecular diagnostics. The therapeutic implications are being realized …
An abstract is unavailable.
The current health care economy has driven many employers to self-funding models to offer affordable health care coverage to employees.
We’re thrilled to announce that the Program in Physical Therapy has been named THE #1 Physical Therapy Program in the Country by US News and…
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible…
In the frontline, patient body mass index plays a prognostic role when using atezolizumab plus bevacizumab vs lenvatinib for patients with advanced hepatocellular carcinoma.